CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for NicOx SA is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

NicOx SA
Drakkar 2 - Batiment D
2405 route des Dolines
Phone: +33 497245300p:+33 497245300 VALBONNE, 06560  France Ticker: ALCOXALCOX
Business Summary
Nicox SA is a France-based international ophthalmic company. It is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The Company has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). It has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board DamianMarron 62 7/16/2024 1/1/2002
Chief Executive Officer, Member of the Management Committee GavinSpencer 53 2/28/2024 1/1/2005
Vice President - Finances, Member of the Management Committee SandrineGestin 53 1/1/2019 1/1/2015
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Aciex Therapeutics, Inc. 470 Atlantic Avenue Boston MA United States

Business Names
Business Name
0RCQ
Aciex Therapeutics, Inc.
ALCOX
8 additional Business Names available in full report.

General Information
Number of Employees: 5 (As of 6/30/2024)
Outstanding Shares: 49,859,431 (As of 8/20/2024)
Shareholders: 5
Stock Exchange: EPA
Fax Number: +33 497245399


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024